|1.||Schally, Andrew V: 16 articles (05/2013 - 09/2002)|
|2.||Nagy, Attila: 9 articles (11/2005 - 09/2002)|
|3.||Halmos, Gabor: 6 articles (05/2013 - 09/2003)|
|4.||Schally, A V: 5 articles (05/2013 - 08/2000)|
|5.||Szepeshazi, Karoly: 4 articles (05/2013 - 10/2003)|
|6.||Block, Norman L: 4 articles (05/2013 - 01/2011)|
|7.||Gründker, Carsten: 4 articles (01/2009 - 09/2002)|
|8.||Emons, Günter: 4 articles (01/2009 - 09/2002)|
|9.||Szalontay, Luca: 3 articles (05/2013 - 07/2012)|
|10.||Vidaurre, Irving: 3 articles (05/2013 - 07/2012)|
01/01/2009 - "A recently finished phase I study assessed the dose limitations, maximum tolerated dose and pharmacokinetics of AN-152 given once every 3 weeks in patients with gynecological and breast cancers. "
03/01/2013 - "AN-152 nearly completely abolished tumor progression and elicited remarkable apoptosis in vitro. "
03/01/2013 - "Treatment of nude mice with AN-152, once a week at an intravenous dose of 413 nmol/20 g, for six weeks resulted in 76 % reduction in tumor growth. "
07/01/2012 - "DOX activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, while AN-152 had no or less such effect. "
07/01/2012 - "The effect of analog, AN-152, on growth of these tumor lines xenografted into nude mice was analyzed. "
|2.||Endometrial Neoplasms (Endometrial Cancer)
01/01/2011 - "The toxicity, pharmacokinetics and maximum tolerated doses of AN-152 were assessed in a phase I clinical trial in women with ovarian or endometrial cancer. "
09/01/2002 - "AN-152 could be considered for targeted chemotherapy in patients with ovarian or endometrial cancers."
10/01/2004 - "AN-152 is internalized through the LHRH-R and induces apoptosis in LHRH-R-positive human ovarian and endometrial cancer cell lines without activating the MDR-1 efflux pump system. "
11/01/2000 - "Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines."
04/01/2005 - "Experimental study using athymic nude mice bearing xenografts of HEC-1A and RL-95-2 human endometrial cancers to assess the efficacy and toxicity of AN-152 and AN-207. "
|3.||Prostatic Neoplasms (Prostate Cancer)
10/01/2003 - "In nude mice bearing intraosseous C4-2 prostate cancers, treatment with AN-152 decreased serum PSA levels (P < 0.01) to 10.3 +/- 3.4 ng/ml from 24.8 +/- 4 ng/ml in controls, whereas DOX had no effect on PSA. "
10/01/2003 - "Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers."
01/01/2011 - "Phase I/II studies with AN-152 in men with hormone-independent relapsed prostate cancer and patients with pancreatic and bladder cancers are pending. "
11/01/2005 - "Both AN-152 and AN-207 can effectively inhibit the growth of LHRH receptor-positive human breast, ovarian, endometrial, and prostate cancers xenografted into nude mice. "
10/01/2003 - "In animals bearing MDA-PCa-2b prostate cancers, therapy with AN-152 for 25 days resulted in a 69% inhibition of tumor growth (P < 0.01 versus controls) and was more effective (P < 0.05) than equimolar doses of DOX or microcapsules of LH-RH agonist Decapeptyl. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
12/03/1997 - "The growth of UCI-107 ovarian cancers was not inhibited by AN-152. "
12/03/1997 - "This study was conducted to investigate the effects of AN-152 on the growth of LH-RH receptor-positive OV-1063 human epithelial ovarian cancers. "
10/01/2004 - "Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system."
09/01/2002 - "Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice."
01/01/2009 - "Thus, cytotoxic LHRH analogues such as AN-152 appear to be suitable drugs for a more efficacious and less toxic targeted chemotherapy for endometrial and ovarian cancers. "
|5.||Breast Neoplasms (Breast Cancer)
01/01/2006 - "A first clinical trial with AN-152 was initiated recently in breast cancer patients."
03/01/1999 - "In this study, we examined binding of AN-152 and AN-207 to membranes of human breast cancer specimens and MCF-7 and MDA-MB-231 human breast cancer lines. "
10/01/2004 - "The cytotoxic LHRH analog AN-152 induces apoptosis independent of MDR-1 in LHRH-R positive breast cancer cells. "
10/01/2004 - "We compared the effects of AN-152 and doxorubicin in human breast cancer cells. "
10/01/2004 - "Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system."
|1.||Gonadotropin-Releasing Hormone (GnRH)
|4.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|5.||AN 204 (AN 201)
|8.||Messenger RNA (mRNA)
|9.||Epidermal Growth Factor Receptor (EGF Receptor)
|10.||Epidermal Growth Factor (EGF)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)